-- Nxera Pharma（东京证券交易所代码：4565）周一在东京证券交易所提交的文件显示，该公司将根据与艾伯维（AbbVie）的神经系统疾病研究合作协议，获得1000万美元的里程碑付款。 这笔款项标志着双方合作的第三个里程碑，与针对神经系统疾病的已验证候选药物的发现挂钩。 根据协议，Nxera 有权获得总计高达12亿美元的里程碑付款，以及未来销售额的分级特许权使用费。该合作项目于2022年启动，利用Nxera专注于G蛋白偶联受体（GPCR）的药物发现平台，开发针对尚未满足的神经系统疾病需求的新疗法。
Related Articles
Equities
Lu'an Environmental Energy 2025 Profit Down 54%; Shares Up 3%
Shanxi Lu'an Environmental Energy Development (SHA:601699) posted 2025 attributable net profit of 1.12 billion yuan, down 54% from 2.45 billion yuan the previous year.Earnings per share declined to 0.37 yuan from 0.82 yuan, according to a weekend filing with the Shanghai bourse.Operating revenue fell 22% year over year to 27.8 billion yuan from 35.9 billion yuan.Shares of the coal miner rose 3% in recent trade.
$SHA:601699
Asia
WA1 Resources Reports AU$131 million Cash Balance at End of Q1, Shares Up 7%
WA1 Resources (ASX:WA1) reported a cash balance of about AU$131 million as at March 31, according to a Monday Australian bourse filing.The company said it has now received all data inputs for a mineral resource estimate update expected in the June quarter.The company completed essential data capture activities in 2025, which is now facilitating project development studies, permitting and approvals workstreams, the filing added.The company's shares rose 7% in recent Monday trade.
$ASX:WA1
Asia
Bank of Ningbo Q1 Profit, Operating Income Up 10%
Bank of Ningbo (SHE:002142) posted first-quarter attributable net profit of 8.18 billion yuan, up 10% from 7.42 million yuan the previous year.Earnings per share rose to 1.24 yuan from 1.12 yuan, according to a weekend filing with the Shenzhen bourse.Operating income rose 10% year over year to 20.4 billion yuan from 18.5 billion yuan.Shares of the bank rose 3% in recent trade.
$SHE:002142